Literature DB >> 455333

Preliminary phase I study of 4'-epi-adriamycin.

V Bonfante, G Bonadonna, F Villani, G Di Fronzo, A Martini, A M Casazza.   

Abstract

A phase I study of 4'-epi-Adriamycin (4'-epi-ADM) was performed in 22 patients with various types of advanced solid tumors. Very preliminary results would indicate that the drug produces a pattern of acute toxicity which is similar to that of Adriamycin. However, the incidence of vomiting, alopecia, and marrow suppression was less pronounced than that of Adriamycin. 4'-Epi-ADM prolonged the systolic time interval, although no patient presented clinical signs of cardiotoxicity. Two patients with renal carcinoma and malignant melanoma showed objective improvement. Present results suggest that further clinical studies with 4'-epi-ADM are indicated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455333

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  25 in total

1.  Hemodynamic effects of chronic 4'epi-adriamycin administration.

Authors:  J Milei; J J Ale; G Garay; F Otero; A Z Comba; H O Gugliotta; R A Storino
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 2.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 3.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.

Authors:  D A Vorobiof; M Iturralde; G Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 5.  Cancer chemotherapy: new developments and changing concepts.

Authors:  S K Carter
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

6.  Phase II study of epirubicin in advanced malignant melanoma.

Authors:  M Lopez; C F Perno; P Papaldo; L Di Lauro; F Ganzina; A Barduagni
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.

Authors:  K Kolarić; V Potrebica; J Cervek
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.

Authors:  J Schütte; N Niederle; B Grunenberg; W Krischke; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

10.  A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.

Authors:  A Martoni; M Giovannini; L Tomasi; C M Camaggi; B Bellanova; N Monetti; G Rossini; M Tarquinii; A Martini; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.